Five Prime Therapeutics Announces FPA150 Poster Presentation at the 2019 ASCO Annual Meeting
– Phase 1a/1b Study of First-in-class B7-H4 Antibody as Monotherapy in Patients with Advanced Solid Tumors –
Data will be presented from the Phase 1a/1b study of FPA150, which is a first-in-class B7-H4 antibody. The Phase 1a dose escalation portion of the study is being conducted in patients with advanced solid tumors and the Phase 1b expansion is enrolling patients with breast, ovarian and endometrial tumors that overexpress B7-H4.
Here are the details of the upcoming poster presentation:
|Poster Title:||Phase 1a/1b Study of First-in-class B7-H4 Antibody, FPA150 as Monotherapy in Patients with Advanced Solid Tumors|
|Poster Session:||Developmental Immunotherapy and Tumor Immunobiology|
|Date & Time:||Saturday, June 1, 2019, 8:00 – 11:00am|
The poster abstracts will be available on
FPA150 is a novel, fully human, afucosylated monoclonal antibody targeting B7-H4. B7-H4 expression is observed in multiple solid tumors, including breast and gynecologic cancers. FPA150 is designed with a dual mechanism of action: blocking the T cell checkpoint activity of B7-H4 as well as enhanced ADCC against tumor cells expressing B7-H4.
Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Words
such as "may," "will," "expect," "plan," "anticipate," "estimate,"
"intend" and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are intended to
identify forward-looking statements. These forward-looking statements
are based on Five Prime's expectations and assumptions as of the date of
this press release. Each of these forward-looking statements involves
risks and uncertainties. Actual results may differ materially from these
forward-looking statements. Factors that may cause actual results to
differ from those expressed or implied in the forward-looking statements
in this press release are discussed in Five Prime’s filings with
Media and Investor Contact
VP, Investor Relations & Corporate Communications
Five Prime Therapeutics, Inc.